Howard Chang on drug mechanism
From Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer · · OncLive
“We are investigating an agent called trebanib, which is a peptibody designed to block angiopoietin 1 and 2, thereby blocking angiogenesis.”
On , Howard Chang, Senior VP of Global Research & Chief Scientific Officer at Amgen, spoke about drug mechanism during Dr. Chang on the TRINOVA-1 Trial in Ovarian Cancer on OncLive.
About Howard Chang
In a 2013 interview, Howard Chang discussed the TRINOVA-1 trial, which he described as part of a series of studies Amgen had been conducting in patients with ovarian cancer. He stated that the trial was investigating an agent called trebanib, a peptibody designed to block angiopoietin 1 and 2, thereby blocking angiogenesis. Chang noted that TRINOVA-1 was a randomized study in recurrent and relapsed ovarian cancer, using weekly paclitaxel as the backbone chemotherapy, with patients receiving either trebanib or placebo.